Xcout Intel
Biograil
Biograil ApS is a Copenhagen-based pre-clinical stage pharmaceutical and biotech company developing a unique oral device for the delivery of therapeutics. The company collaborates with major industry partners like CSL.
Subscribe to see Biograil’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Biograil at a glance
Biograil is a healthcare company headquartered in Denmark. It has raised at least $10M across the 2 funding rounds on record, 1 of them with a disclosed amount. Its most recent funding round, Series A, raised $10M in July 2025. Xcout tracks 7 named people at Biograil, including Karsten Lindhardt (CEO).
Biograil leadership
- Karsten LindhardtCEO
- Karsten LindhardtBoard Member, CEO & Founder
- Steffen WagnerBoard Member, Co-founder and Co-CEO, Verve Ventures
- John M. BarberichChairman of the Board, Consulting CFO & Founder
- Lars Hellerung ChristiansenBoard Member, Private investor & Founder
- Robert RadieBoard Member, CEO, Neuraptive Therapeutics
1 more named person on record for Biograil, with roles, board committees and tenure — see the full roster →
Biograil funding rounds
At least $10M raised across the 2 rounds on record (1 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $10M | 4 named | |
| Seed | Undisclosed | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Biograil competitors
A few of Biograil's closest competitors — see the full list of competitors and alternatives →
Enzymatica develops health solutions and barrier technology products, such as the ColdZyme mouth spray, designed to support the body's defense against viruses and micro-organisms. The company serves consumers looking to prevent or alleviate common cold symptoms and respiratory infections.
Corline Biomedical provides antithrombotic and anti-inflammatory surface coating solutions, primarily utilizing its macro-molecular heparin technology (CHS) for the medical device industry. The company also develops applications for regenerative medicine, including products such as Renaparin for kidney transplantation and Cytoparin for cell therapy and diabetes treatment.
Biora Therapeutics is a U.S. biotechnology company developing ingestible, device-based platforms for delivering biologic medicines to targeted areas of the gastrointestinal tract and into systemic circulation. Its technologies are intended for use by pharmaceutical and biotechnology companies developing oral or targeted biologic therapies.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Micron Biomedical, Inc. is a clinical-stage biopharmaceutical and life science company committed to expanding global access to therapeutics and vaccines formulated into proprietary array-based delivery technologies.
Prime Life Sciences is a biotechnology company specialized in pharmacy, biotechnology, and medical devices. Launched in 2020, it is headquartered in Basel, Switzerland, delivering targeted solutions across various healthcare sectors.
Get Biograil's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Biograil in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access